Medicare payment in January helps MD Anderson reduce its operating losses

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MD Anderson Cancer Center reduced its year-to-date operating loss to $77.3 million in January, the fifth month of the fiscal year.

In January, the cumulative operating loss was $169.4 million. The loss shrunk because in January MD Anderson booked about $63.4 million in a settlement from Medicare, which allowed the cancer center to claim a portion of its expenses for implementing the Epic system.

Due to increased clinical activity by about 10 percent from December to January, operating revenues were around $28.7 million. This the first monthly positive margin since Epic’s rollout in March 2016.

In an interview with The Cancer Letter, MD Anderson Chief Operating Officer Steve Hahn said the installation, which he described as the largest in the history of Epic, changed over the cancer center’s inpatient, outpatient and billing systems at the same time.

Hahn, deputy to the president, said the installation of Epic exposed and exacerbated inefficiencies in the cancer center’s operations.

The text of the interview with Hahn appears here.

The cancer center’s financials appear below:

MD Anderson Cancer Center Monthly Financials,
September 2016 to January 2017

MDACC-1

Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login